Double-Punch immunotherapy trial aims to control tough lymphoma
NCT ID NCT06213311
Summary
This study is testing a combination of two immunotherapy drugs for people with a type of blood cancer called large B-cell lymphoma that has returned or didn't respond to first treatment. The goal is to see if using a personalized cell therapy (axi-cel) together with a targeted antibody drug (glofitamab) is safe and can help control the cancer. The study will enroll about 40 adults whose cancer came back within a year of their initial therapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.